About Shawn

Shawn focuses his practice on developing business-oriented patent strategies for biotechnology, pharmaceutical and medical device companies in the US and abroad. His work includes drafting and prosecuting patent applications, preparing freedom to operate opinions, and counseling clients on US Food and Drug Administration exclusivity strategies. Shawn has also represented many prominent life sciences investors in intellectual property due diligence matters for numerous financing transactions, including licensing, venture capital financings, initial public offerings and M&A transactions. He has worked on multiple patent litigation matters before the US Patent and Trademark Office – including inter partes review and post-grant review proceedings – and provided litigation support in district court cases. In addition, Shawn also co-chairs the Asian Pacific Islander Affinity Group at Cooley.

View full bio

Passions

Reading

Traveling

Tech gadgets

Experience

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

July 27, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Frances Stocks Allen
Partner, London
Jiqiang Lin
Associate, New York
Freddy Yip
Associate, Hong Kong
Aaron Pomeroy
Partner, Colorado
David Wilson
Partner, London
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Robert Eisenbach
Of Counsel, San Francisco
Navya Dasari
Associate, New York
Rick Jantz
Associate, Santa Monica
Eerik Kukebal
Associate, London
Daniel Millard
Associate, London
Patrick Sharma
Associate, Santa Monica
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Life Sciences and Healthcare Regulatory
Tax
Cyber/Data/Privacy
Business Restructuring
Antitrust and Competition
Patent Counseling and Prosecution
Asia

Earendil Labs Announces Worldwide Exclusive License Agreement With Sanofi

Earendil Labs Announces Worldwide Exclusive License Agreement With Sanofi

April 17, 2025

Cooley advised Earendil Labs, an artificial intelligence-driven biotech company affiliated with Helixon Therapeutics, in connection with Earendil Labs’ license agreement with Sanofi for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.

Read more

Related contacts

Geoffrey Spolyar
Partner, Boston
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Zack Gong
Associate, Shanghai
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Capital Markets
Patent Counseling and Prosecution
Tax
Antitrust and Competition
CFIUS

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

June 14, 2023

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Asia
Tax

LumiraDx Limited – $100.3 Million Follow-on Offering and Concurrent Private Placement

LumiraDx Limited – $100.3 Million Follow-on Offering and Concurrent Private Placement

August 24, 2022

Cooley advised the underwriters in LumiraDx Limited’s $100.3 million aggregate financing, consisting of (1) a $75.3 million follow-on offering of 43,000,000 shares of common stock at a public offering price of $1.75 per share and (2) a $25.0 million concurrent private placement with the Bill & Melinda Gates Foundation. LumiraDx is a diagnostics company manufacturing and commercializing an innovative diagnostic platform that supports a broad menu of tests with lab-comparable performance at the point of care. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Valerie Sapozhnikova
Associate, Los Angeles
Jesse Schulman
Associate, Colorado
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC

Related Practices & Industries

Capital Markets
Life Sciences
Healthcare

SOPHiA Genetics – $234 Million IPO

SOPHiA Genetics – $234 Million IPO

July 23, 2021

Cooley advised the underwriters on SOPHiA Genetics’ $234 million initial public offering of 13,000,000 ordinary shares. J.P. Morgan Securities LLC, Morgan Stanley & Co., Cowen and Company, LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. SOPHiA Genetics, whose securities now trade on the Nasdaq Global Select Market under the symbol “SOPH,” is the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine. Partners Richard Segal, Div Gupta and Eric Blanchard led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Eric Blanchard
Partner, Boston
Darah Protas
Partner, Washington, DC
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC

Related Practices & Industries

Capital Markets
Life Sciences
View more

Admissions and credentials

California

District of Columbia

Registered to practice before the United States Patent and Trademark Office (USPTO)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.